Carl Atkinson to Recombinant Fusion Proteins
This is a "connection" page, showing publications Carl Atkinson has written about Recombinant Fusion Proteins.
Connection Strength
2.036
-
In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
Score: 0.674
-
Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol. 2010 Dec 01; 185(11):7007-13.
Score: 0.319
-
Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol. 2008 Jan 15; 180(2):1231-8.
Score: 0.264
-
Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
Score: 0.125
-
A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1728-37.
Score: 0.117
-
Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
Score: 0.108
-
Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
Score: 0.094
-
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
Score: 0.070
-
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol. 2006 Sep; 169(3):1039-47.
Score: 0.060
-
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
Score: 0.056
-
Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med. 2014 Aug 25; 211(9):1793-805.
Score: 0.026
-
A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
Score: 0.023
-
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
Score: 0.022
-
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
Score: 0.021
-
Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol. 2011 Oct; 45(4):834-42.
Score: 0.021
-
A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009 Oct 01; 183(7):4764-72.
Score: 0.019
-
A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009 Aug; 119(8):2304-16.
Score: 0.018